Rheumatoid arthritis (RA) is a chronic autoimmune disease. It is characterized by severe joint destruction due to inflammatory synovitis. There are several factors that have a strong link in the initiation and progression of RA. Albeit the exact cause of disease initiation is still elusive. It is currently understood that RA is a multifactorial disease in which the total risk of disease susceptibility, persistence, and severity are determined by intricate interactions between the host and particular inflammatory mediators in order to lessen symptoms. Doctors are generally using the drugs such as disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCs), and biological agents in the treatment of RA patients. These traditional drugs have some disadvantages including low patient compliance, the failure to halt the disease's development, and safety concerns. Therefore, to overcome these issues, it is imperative to create innovative drug delivery vehicles that may improve safety evaluation and deliver therapeutics drugs to inflammatory synovial regions efficiently. From this perspective, nanotechnology shows great promise in developing new carriers for the management of RA and maybe a future alternative to conventional treatment approaches for RA. Many flexible nanocarriers with distinct physicochemical properties, and individualized drug release patterns were developed in order to increase the efficacy of drugs in the treatment of RA. In this chapter, we have covered in-depth the nanocarriers that are currently being used to treat RA in a preclinical setting and its future perspective.